TGF-β1 and Endothelial/Tissue Injury With High-dose Intravenous Iron Therapy in Renal Failure: Evidence or Perception?

Borawski J , Gozdzikiewicz J , Abramowicz P , Naumnik B , Mysliwiec M. Endothelial injury markers with high-dose intravenous iron therapy in renal failure. Clin Appl Thromb Hemost 2004; 10: 403-403.

Grainger DJ , Mosedale DE , Metcalfe JC. TGF-βin blood: A complex problem. Cytokine Growth Factor Rev 2000; 11: 133-133.

Saharinen J , Hyytiainen M , Taipale J , Keski-Oja J. Latent transforming growth factor-beta binding proteins (LTBPs)—structural extracellular matrix proteins for targeting TGF-beta action. Cytokine Growth Factor Rev 1999; 10: 99-99.

Shah SV , Alam MG. Role of iron in atherosclerosis. Am J Kidney Dis 2003; 41(suppl 1): S80-S80.

Agarwal R , Vasavada N , Sachs NG , Chase S. Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. Kidney Int 2004; 65: 2279-2279.

Grainger DJ. Transforming growth factor-βand atherosclerosis: So far, so good for the protective cytokine hypothesis. Arterioscler Thromb Vasc Biol 2004; 24: 399-399.

Junker U , Haufe CC , Nuske K , et al. Elevated plasma TGF-β1 in renal diseases: Cause or consequence? Cytokine 2000; 12: 1084-1084.

Harris H , Kirschenlohr H , Szabados N , Metcalfe J. Transforming growth factor-β1 inhibits thrombin activation of endothelial cells. Cytokine 2004; 25: 85-85.

Stefoni S , Cianciolo G , Donati G , et al. Low TGF-β1 serum levels are a risk factor for atherosclerosis disease in ESRD patients. Kidney Int 2002; 61: 324-324.